Welcome to our dedicated page for Trevi Therapeutics SEC filings (Ticker: TRVI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trevi Therapeutics, Inc. (TRVI) SEC filings page on Stock Titan provides access to the company’s public reports filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biopharmaceutical company, Trevi uses SEC filings to disclose financial results, material corporate events, and risk factors related to the development of its investigational therapy Haduvio™ (oral nalbuphine extended-release) for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
On this page, you can review current reports on Form 8-K that Trevi files to announce quarterly financial results, changes in key executives, and other significant developments. These 8-K filings often reference press releases that summarize clinical progress, such as data from the Phase 2b CORAL trial in IPF chronic cough and the Phase 2a RIVER trial in RCC, as well as updates on regulatory interactions and planned studies.
In addition to 8-Ks, Trevi’s broader SEC reporting (such as Forms 10-Q and 10-K, when available) contains detailed information on research and development expenses, liquidity, and the risks and uncertainties associated with advancing Haduvio through clinical trials and regulatory review. These documents also describe forward-looking statements regarding future plans for chronic cough indications and capital resources.
Stock Titan’s filings interface is designed to surface Trevi’s SEC documents as they are posted to the EDGAR system and to pair them with AI-generated highlights. These summaries can help explain the key points of lengthy filings, including how Trevi characterizes its clinical-stage status, its focus on IPF, non-IPF ILD, and RCC, and the factors that may affect its business and TRVI stock.
Trevi Therapeutics reported fourth-quarter and full-year 2025 results and outlined plans to advance its chronic cough pipeline. The company is developing Haduvio, an oral nalbuphine extended-release therapy for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.
Trevi ended 2025 with $188.3 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2028. For 2025, research and development expenses fell to $33.5 million from $39.4 million, while general and administrative costs rose to $15.9 million from $12.1 million. The net loss narrowed to $42.8 million from $47.9 million in 2024.
The company gained overall FDA alignment on its Phase 3 program for IPF-related chronic cough and plans two pivotal Phase 3 trials beginning in 2026. It also plans Phase 2b trials in 2026 for refractory chronic cough and for non-IPF ILD-related chronic cough, and will host an Investor and Analyst Day on May 7, 2026.
Trevi Therapeutics, Inc. is moving its lead program for IPF-related chronic cough into late-stage testing after reaching overall alignment with the U.S. Food and Drug Administration at an End-of-Phase 2 meeting. The company plans two pivotal Phase 3 trials of nalbuphine ER tablets, both randomized, double-blind, placebo-controlled, multicenter and global, using a 54 mg twice-daily dose.
The first trial is planned to enroll about 300 patients with 52 weeks of fixed dosing and a primary endpoint at 24 weeks. The second trial is planned to enroll about 130 patients with 12 weeks of fixed dosing. In both, patients will be randomized 2:1 to nalbuphine ER or placebo, and the primary efficacy endpoint will be the relative change from baseline in 24-hour cough frequency, measured by an objective cough monitor. These designs remain subject to the FDA’s final protocol review.
Cassella James V reported acquisition or exercise transactions in this Form 4 filing.
Trevi Therapeutics, Inc. reported that Chief Development Officer James V. Cassella received a grant of stock options covering 215,000 shares of common stock on February 19, 2026. The options were granted at a price of $0.0000 per share as a compensation award.
The 215,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, and vesting depends on Cassella’s continued service with the company. Following this award, he holds stock options for 215,000 shares directly.
Trevi Therapeutics, Inc. reported that company officer Christopher Galletta received a grant of stock options covering 35,000 shares of common stock. The award was made on February 19, 2026 as a compensation-related acquisition, not an open-market purchase.
The 35,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, conditioned on Galletta’s continued service with the company. This filing simply records the new equity award and Galletta’s resulting direct ownership of these options.
Trevi Therapeutics, Inc. reported that its Chief Scientific Officer, Thomas Sciascia, received a grant of stock options covering 85,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase. According to the filing, these 85,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, and the vesting is conditioned on his continued service with the company.
Trevi Therapeutics, Inc. reported that President and CEO Jennifer L. Good received a grant of stock options covering 675,000 shares of common stock. The award was granted on February 19, 2026 at no cost on grant and represents a compensation-related acquisition, not an open-market purchase.
The 675,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, so long as she continues her service with the company. This structure ties the potential ownership benefit to her ongoing tenure over the multi-year vesting period.
Simon Farrell reported acquisition or exercise transactions in this Form 4 filing.
Trevi Therapeutics Chief Commercial Officer Simon Farrell received a grant of stock options covering 160,000 shares of common stock. The award was made on February 19, 2026 as an equity incentive.
The 160,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, conditioned on Farrell’s continued service with the company.
Rubric Capital Management LP and David Rosen report beneficial ownership of 3,766,749 shares of Trevi Therapeutics, Inc. common stock, equal to 2.94% of the outstanding shares based on 128,230,134 shares as of October 31, 2025. They share voting and dispositive power over all reported shares and indicate that the position is held in the ordinary course of business. They state the holdings were not acquired and are not held to change or influence control of Trevi Therapeutics.
Trevi Therapeutics, Inc. received an updated Schedule 13D/A from New Enterprise Associates–affiliated funds and managers, correcting earlier disclosures after exercises of certain NEA 16 warrants and acquisition of the underlying common shares before Amendment No. 7.
As of February 13, 2026, the NEA funds report beneficial ownership of a combined 15,074,080 shares of Trevi common stock, representing 11.6% of the class, based on 130,081,986 shares including NEA 16 warrants. This includes 12,273,280 shares held by NEA 16 and 948,948 shares held by NEA 18 Venture Growth Equity, plus 1,851,852 shares underlying NEA 16 warrants. Individual manager Forest Baskett is deemed to beneficially own 14,125,132 shares, or 10.9%. The filing states the firm shares were acquired for investment purposes and notes no specific current plans for corporate changes, though the funds may buy or sell additional shares over time.
Trevi Therapeutics reported that investment manager FMR LLC, together with Abigail P. Johnson, has filed a Schedule 13G showing beneficial ownership of 6,500,009.33 shares of Trevi common stock, representing 5.1% of the class as of 12/31/2025.
FMR LLC has sole voting power over 6,485,775 shares and sole dispositive power over the full 6,500,009.33 shares, with no shared voting or dispositive power. The securities were acquired and are held in the ordinary course of business, and not with the purpose or effect of changing or influencing control of Trevi.